RBC Capital Keeps Their Buy Rating on RioCan Real Estate Investment (RIOCF)
In a report released today, Pammi Bir from RBC Capital maintained a Buy rating on RioCan Real Estate Investment (RIOCF – Research Report), with a price target of C$21.00. The company’s shares closed last Friday at $11.99.
Light Up your Portfolio with Spark:
- Easily identify stocks' risks and opportunities.
- Discover stocks' market position with detailed competitor analyses.
According to TipRanks, Bir is a 4-star analyst with an average return of 8.0% and a 53.68% success rate. Bir covers the Real Estate sector, focusing on stocks such as RioCan Real Estate Investment, NorthWest Healthcare Properties REIT, and Dream Office Real Estate Investment.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for RioCan Real Estate Investment with a $15.02 average price target, a 25.27% upside from current levels. In a report released on March 20, CIBC also maintained a Buy rating on the stock with a C$22.00 price target.
The company has a one-year high of $15.40 and a one-year low of $11.43. Currently, RioCan Real Estate Investment has an average volume of 67.77K.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RIOCF in relation to earlier this year.
Read More on RIOCF:
Questions or Comments about the article? Write to editor@tipranks.com- RioCan Addresses Impact of Hudson’s Bay CCAA Filing
- RioCan REIT downgraded to Hold from Buy at Canaccord
- RioCan Real Estate Investment Downgraded to Hold Amid Hudson’s Bay Co. Financial Struggles and Revised Forecasts
- RioCan REIT price target raised to C$21.50 from C$20.50 at BMO Capital
- Strong Buy Rating for RioCan Real Estate Investment Driven by Robust 2024 Performance and Strategic Growth Plans
